MedPath

Effect of tretinoin nano lipid on acne

Phase 2
Conditions
acne.
Acne vulgaris
Registration Number
IRCT20161207031288N2
Lead Sponsor
Jarfandishan-e Navid-e Salamat (Janus) knowledge-based company
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
20
Inclusion Criteria

1.Aged between 12 to 40 years
2.10 -50 acne lesions
3.No change in diet and life style during the study
4.Signed informed consent voluntarily and knowingly

Exclusion Criteria

Long-time exposure to UV radiation
History of sensitivity to topical anti acne drug therapy
Use of topical anti acne drug therapy including AHA, BHA, benzyl peroxide, vitamin A, retin-A, antibiotics within one month prior to the study
Pregnancy / breastfeeding
History of systemic antibiotics for acne treatment within one month prior to the study

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Modified acne severity index. Timepoint: Beforeintervention, one mouthlater ,two mounth after intervention. Method of measurement: MPA580.
Secondary Outcome Measures
NameTimeMethod
Skin PH. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Skin sebum. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Skin melanin and erythem. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Transepidermal water loss. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Hydration. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Size and value of acne. Timepoint: Before and after 4 and 8 weeks. Method of measurement: Visiopor.
© Copyright 2025. All Rights Reserved by MedPath